Home/Pipeline/GABA-A PAM for Epilepsy

GABA-A PAM for Epilepsy

Epilepsy

PreclinicalActive

Key Facts

Indication

Epilepsy

Phase

Preclinical

Status

Active

Company

Modulate Bio

About Modulate Bio

Modulate Bio is a private, pre-revenue biotech founded in 2021, leveraging a proprietary platform to design selective GABA-A PAMs for neurological disorders. The company is nearing a development candidate for Essential Tremor, its lead program, with a pipeline that includes epilepsy and anxiety. Backed by academic roots from Harvard and Brigham and Women's Hospital, the team combines deep drug discovery expertise with a clear focus on validated targets with significant unmet medical need.

View full company profile

Therapeutic Areas

Neurology Psychiatry

Other Epilepsy Drugs

Drug	Company	Phase	Status
ADX71149 (mGlu2 PAM)	Addex Therapeutics	Phase 2	Active (with Janssen)
TRV045	Trevena	Phase 1	Active
SAGE-324	Sage Therapeutics	Preclinical	Research
Motpoly XR™	Aucta Pharmaceuticals	Not Specified (Likely Phase 3/NDA)	Active
ADB-104	Adolore BioTherapeutics	Pre-clinical	Active
Not Publicly Disclosed	Cerecin	Phase 2	Active
eTNS Platform	NeuroSigma	Unknown	Active
NPT 2042	NeuroPro Therapeutics	Phase 2	Active
Spritam (levetiracetam)	Aprecia Pharmaceuticals	Approved	Active
Perampanel	Ark Diagnostics	In Development	Active
NeuroAccess Platform	Cordance Medical	Pre-clinical/Research	Active
Epilepsy Program	Current Surgical	Research	Active